Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Hum Genet. 2014 Aug 10;134(5):497–507. doi: 10.1007/s00439-014-1470-0

Table 3.

Classifying HNSCC progression-free survival (PFS) and overall survival (OS) for different HNSCC patient subgroups using the rules devised in Poeta et al. with and without splice-site consideration

Surgical group Survival Classifier HR (D vs. ND) HR, 95 % CI P value
All patients with mutated TP53 (n = 224) PFS Poeta rules + Splice 1.50 1.10–2.04 0.01
Poeta rules 1.43 1.04–1.95 0.03
OS Poeta rules + Splice 1.34 0.96–1.89 0.09
Poeta rules 1.40 1.00–1.98 0.05
Recurrent only (n = 39) PFS Poeta rules + Splice 2.12 1.07–4.22 0.03
Poeta rules 2.08 1.04–4.16 0.04
OS Poeta rules + Splice 1.93 0.92–4.03 0.08
Poeta rules 2.50 1.19–5.23 0.02
Surgery only (n = 69) PFS Poeta rules + Splice 1.98 1.10–3.57 0.02
Poeta rules 1.72 0.93–3.17 0.08
OS Poeta rules + Splice 1.30 0.68–2.48 0.42
Poeta rules 1.03 0.51–2.08 0.94
Surgery + postoperative therapy (n = 114) PFS Poeta rules + Splice 1.21 0.78–1.87 0.40
Poeta rules 1.18 0.76–1.82 0.47
OS Poeta rules + Splice 1.28 0.79–2.09 0.31
Poeta rules 1.42 0.88–2.30 0.16
Surgery only combined with surgery + postoperative therapy (n = 183) PFS Poeta rules + Splice 1.45 1.02–2.06 0.04
Poeta rules 1.33 0.93–1.90 0.11
OS Poeta rules + Splice 1.28 0.87–1.89 0.21
Poeta rules 1.26 0.85–1.86 0.25

HR is the hazard ratio calculated for disruptive (D) vs. non-disruptive (ND) classifications, CI is the confidence interval, and n is the number of patients in the corresponding subgroup

Results for All patients with mutated TP53 are shown for comparison, and are the same as in Tables 1 or 2